2025 Agenda

logologo

Draft agenda – subject to change

*All times are in EST

Sep

Fri 19

10:00AM -12:00PM

iwAL MRD working group session
Chairs: Naval Daver & Andrew Wei

 

Part 1: Prognostic implications

  • Flow cytometry: Sanam Loghavi
  • NPM1: Jad Othman
  • FLT3: Christopher Hourigan
  • Should we intervene at MRD persistence or recurrence?: Farhad Ravandi

 

Part 2: Endpoints for clinical trials: Michael Heuser

 

Part 3: MRD-directed therapies

  • MRD intervention trials – learnings from INTERCEPT: Andrew Wei
  • Talk title TBC: Naval Daver

 

Part 4: FDA perspective

  • FDA clinical perspective: TBC
  • FDA statistical perspective: TBC
  • FDA devices perspective: TBC

 

Part 5: Panel discussion

2:00PM -2:10PM

Welcome & introduction
Naval Daver

2:10PM -2:45PM

Session 1: Translational and lab developments and applications in AML
Chairs: Ravindra Majeti & Iannis Aifantis

  • Clonal evolution of therapy-related myeloid neoplasms: Koichi Takahashi
  • RAS pathway activation drives resistance to gilteritinib and venetoclax: Catherine Smith

Panel discussion

2:45PM -3:35PM

Session 2: New science implications for AML
Chairs: Koichi Takahashi & Paresh Vyas

  • Stem cells in human AML: Ravindra Majeti
  • Transcriptomic and geographical mapping of extramedullary AML: Iannis Aifantis
  • The aging of the blood system and diagnosis of leukemia from the peripheral blood: Liran Shlush

Panel discussion

3:35PM -4:45PM

Session 3: Transplantation in AML
Chairs: Paresh Vyas & Eytan Stein

  • GVL new approaches: Paresh Vyas
  • Strategies to optimise transplant outcomes: Charles Craddock
  • Debate: Is pre-transplant intervention warranted in patients with MRD+ AML CR1?
    • Yes: Maximilian Stahl
    • No: Roland Walter

Panel discussion

4:45PM -4:55PM

Day 1 conclusions
Naval Daver

Sep

Sat 20

8:00AM -8:10AM

Welcome to Day 2
Naval Daver

8:10AM -9:20AM

Session 4: Updates on established therapies in AML
Chairs: Jessica Altman & Andrew Wei

  • Intensive or non-intensive induction: Curtis Lachowiez
  • Optimal approach to treatment of secondary/therapy-related AML: Tara Lin
  • Improving induction strategies: Tapan Kadia
  • Venetoclax de-escalation: Stéphane de Botton

Panel discussion

9:20AM -10:40AM

Session 5: Immunotherapies in AML
Chairs: Marion Subklewe & Roland Walter

  • Early-phase CAR and γδ T cell immunotherapy trials for R/R AML and MDS: Nelli Bejanyan
  • NK cell-based therapies in AML: Jeffrey Miller
  • TCEs & CAR-T in AML: Let’s try that again: Marion Subklewe
  • Mitigating CRS during immunotherapy for AML: John DiPersio
  • Understanding myeloid neoplasms in patients after CAR-T therapy: Ann-Kathrin Eisfeld

Panel discussion

10:40AM -11:10AM

Break

11:10AM -12:20PM

Session 6: Targeting FLT3-mutant AML
Chairs: Richard Stone & Amir Fathi

  • Designing and applying a FLT3-like signature in AML: Adrián Mosquera Orgueira
  • Frontline approaches for FLT3-mutant AML: Naval Daver
  • Current approaches and challenges for relapsed FLT3-mutant AML: Jessica Altman
  • Managing FLT3-ITD+ AML in remission: who should receive transplant, maintenance, neither,
    or both?: Alexander Perl

Panel discussion

12:20PM -1:10PM

Session 7: International trials group
Chairs: Naval Daver & Charles Craddock

  • UK trials: Charles Craddock
  • US trials: Harry Erba
  • French trials: Christian Recher

Panel discussion

1:10PM -2:10PM

Lunch

2:10PM -2:50PM

Session 8: Value and utility of MRD in the management of adults with newly-diagnosed AML
Chairs: Mark Levis & Farhad Ravandi

  • Debate: MRD is a universally accepted assay/standard of care for the management of fit adults with newly-diagnosed AML
    • For: Sanam Loghavi & Roland Walters
    • Against: Eunice Wang & Justin Watts

Panel discussion

2:50PM -3:10PM

Keynote talk 1
Goldilocks, AML, and the dialectical three: Gail Roboz

 

3:10PM -3:40PM

Break

3:40PM -4:30PM

Session 9: New frontiers in MRD for AML: Regulatory perspective and clinical practice
Chairs: Naval Daver, Gail Roboz & TBC

  • Cell-free DNA determinants of AML MRD: Tian Yi Zhang
  • MRD as a clinical endpoint in clinical trials: Christopher Hourigan
  • Talk title TBC: TBC

Panel discussion

4:30PM -5:40PM

Session 10: Clonal hematopoiesis, BPDCN & CMML
Chairs: Naveen Pemmaraju & Andrew Lane

  • Potential for early intervention in CHIP and CCUS: Updates and ongoing trials: Uma Borate
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Targeting CD123: Naveen Pemmaraju
  • PI3 kinase gamma: A novel target across AML, BPDCN, and CMML: Andrew Lane
  • Future targets and trials progress in CMML: Guillermo Montalbán Bravo

Panel discussion

5:40PM -5:50PM

Day 2 conclusions
Charles Craddock

 

Sep

Sun 21

8:30AM -8:40AM

Welcome to Day 3

8:40AM -9:00AM

Keynote talk 2
Talk title TBC: Charles Craddock

9:00AM -10:10AM

Session 11: Menin inhibition in AML
Chairs: Naval Daver & Andrew Wei

  • Single-agent menin inhibitors – efficacy, biomarkers and resistance: Ghayas Issa
  • Menin inhibitor combinations: Joshua Zeidner
  • Venetoclax or menin inhibitors for NPM1-mutated AML: Eytan Stein
  • Mechanisms of resistance to menin inhibitors: Amir Fathi

Panel discussion

10:10AM -11:00AM

Session 12: TP53-mutated AML
Chairs: David Sallman & Eunice Wang

  • Biological insights: Andrew Wei
  • Future strategies for TP53-mutated AML: How do we improve outcomes?: David Sallman
  • Treating TP53-mutated AML after failure of frontline Ven/HMA: Gabriel Mannis

Panel discussion

11:00AM -11:30AM

Break

11:30AM -12:20PM

Session 13: Novel targets, combinations and treatments in AML (part 1)
Chairs: Tapan Kadia & Gail Roboz

  • IC+VEN in newly diagnosed fit AML – Who are the optimal patients for this approach?: Courtney DiNardo
  • Optimal use of OGM and RNA translocation panel in frontline AML: Sanam Loghavi
  • Overcoming resistance to venetoclax-based therapies in AML: Marina Konopleva

Panel discussion

12:20PM -1:10PM

Session 14: Novel targets, combinations and treatments in AML (part 2)
Chairs: Harry Erba & Ghayas Issa

  • Promising combination options with AZA/VEN for R/R AML: Thomas Cluzeau
  • Emerging combination strategies in AML: Hima Atluri
  • Targeting the root: Novel approaches against leukemic stem cells in AML: Aditi Shastri

Panel discussion

1:10PM -1:20PM

Meeting summary and close
Naval Daver